Headlines

Dr Sivaranjani Santosh: Meet Dr Sivaranjani Santosh: the Hyderabad paediatrician who turned a social media appeal to solve a mother’s impossible Rs 12–13 lakh monthly bill and changed it into hope for 7 children with a rare disorder


Meet Dr Sivaranjani Santosh: the Hyderabad paediatrician who turned a social media appeal to solve a mother’s impossible Rs 12–13 lakh monthly bill and changed it into hope for 7 children with a rare disorder
Photo: @drsivaranjanionline/ Instagram

Families dealing with a rare disease often face problems not only finding a treatment but also paying for it. In Hyderabad, paediatrician Dr Sivaranjani Santosh has helped change that for seven children with Allan-Herndon-Dudley syndrome (AHDS), a rare genetic disorder.She arranged access to a more affordable supply of the medicine Tiratricol, with support from Access to Medicines India and the Pharmaceutical Accountability Foundation. The effort has brought the cost of treatment down sharply for the children’s families.She is one of those who fill up the gaps many refuse and emerge as a Guardian angel for many, and here she changed the lives of as many as 7 children battling a rare disorder.

Meet Dr Sivaranjani Santosh, the Hyderabad paediatrician who turned a social media appeal into hope

Dr Sivaranjani Santosh is a Hyderabad-based paediatrician with 18 years of experience behind her, she focuses on keeping children healthy before problems start. According to Deccan Chronicle, she and K.M. Gopakumar of Access to Medicines India led an effort that gives seven children in India with a rare genetic disorder access to a life-saving medicine from November 30.Along with regular paediatric care, she teaches first aid and CPR, and she guides new mothers on caring for newborns and breastfeeding, according to Magna Centres for Obesity, Diabetes, and Endocrinology. She is also well known for talking about preventive child health on social media, where she spreads health awareness and clears up common myths.

What is AHDS?

The condition Allan-Herndon-Dudley syndrome (AHDS), also called MCT8 deficiency, impairs the transport of thyroid hormones into brain cells, leading to severe neurological and developmental delays, according to a study published in Molecular Genetics and Metabolism.The UK’s NIHR Innovation Observatory describes the drug, tiratricol, as an analogue of the thyroid hormone T3. The US FDA has approved Emcitate (tiratricol) as the first therapy for symptoms of this disease.

Dr. Sivaranjani stepped in to help a 20-month-old boy with a rare disorder

According to ThePrint, Arav, a 20-month-old boy with AHDS, was one of Dr Sivaranjani’s patients. According to Deccan Chronicle his mother, Pavitra Sirolkar, had to arrange around Rs 12-13 lakh for a single month’s supply from Germany; this was not sustainable, since the medicine could be needed for life.Dr Sivaranjani approached pharmaceutical companies and explored compassionate-use options, but could not secure a lasting supply. She also told ThePrint that most families could not pay for treatment themselves, saying “Rs 20,000 per month for lifelong treatment is not feasible.”She posted an appeal on social media to help the patients and it raised lakhs to their helpShe posted an appeal on social media on September 7. It reached the Netherlands-based Pharmaceutical Accountability Foundation (PAF), which explored compounding the medicine, and Transvaal Pharmacy in The Hague developed the formulation.PAF estimated a year’s treatment for all seven children at around €14,200, about Rs 15.08 lakh. Dr Sivaranjani raised around Rs 6.09 lakh in India, and the foundation arranged the rest in the Netherlands.

The children are spread across two cities

ThePrint reports, five of the seven are under the care of Dr Praveen at Christian Medical College (CMC) Vellore, and two, including Arav, are treated by Dr Sivaranjani. On November 30, parents of two children will receive the first batch at her Hyderabad clinic, and the other five families in Bengaluru.Dr Sivaranjani knows this is only a first step. She told Deccan Chronicle that importing cannot be a permanent solution, and asked how a medicine can exist in the world “but not be available for our children.” She plans to approach the Union government with Access to Medicines India to explore making it in India, and is reaching out to doctors to find more children with confirmed or suspected MCT8 deficiency.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *